Condition: Metastatic Cancer · Sponsor: University of Chicago
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
This description comes directly from the study's public registry record.
Personalized Cancer Care Consortium · 773.702.1220 · PhaseIICRA@medicine.bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University Of Chicago Medicine Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| SSM Health Cancer Care | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04295863